[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Is A Strong Buy After The Recent Pullback (Upgrade)",
    "summary": "Vertex Pharmaceuticals Incorporated's stock drop is overblown. With strong CF revenue, pipeline potential, & insider confidence, click for why VRTX stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=33e219893e5ff70d5426b444ee5aa22e2dd7a6608d34f9b1f1e8f72f4863156f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754930844,
      "headline": "Vertex Pharmaceuticals Is A Strong Buy After The Recent Pullback (Upgrade)",
      "id": 136311902,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1372801568/image_1372801568.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Vertex Pharmaceuticals Incorporated's stock drop is overblown. With strong CF revenue, pipeline potential, & insider confidence, click for why VRTX stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=33e219893e5ff70d5426b444ee5aa22e2dd7a6608d34f9b1f1e8f72f4863156f"
    }
  },
  {
    "ts": null,
    "headline": "Should Pfizer Stock Be in Your Portfolio After Solid Q2 Results?",
    "summary": "Pfizer posts strong Q2 earnings and raises EPS outlook, with oncology growth and new drugs offsetting looming headwinds.",
    "url": "https://finnhub.io/api/news?id=657e4b986a3644724c9843d0f2042d9ca363503b15e12a92fd0826893eccf0eb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754917920,
      "headline": "Should Pfizer Stock Be in Your Portfolio After Solid Q2 Results?",
      "id": 136310492,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer posts strong Q2 earnings and raises EPS outlook, with oncology growth and new drugs offsetting looming headwinds.",
      "url": "https://finnhub.io/api/news?id=657e4b986a3644724c9843d0f2042d9ca363503b15e12a92fd0826893eccf0eb"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=9e896234d19a7891de7e282db73ed0811aeab93204434d3c9dc6eaa6b4aa1eeb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754917204,
      "headline": "Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know",
      "id": 136294377,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=9e896234d19a7891de7e282db73ed0811aeab93204434d3c9dc6eaa6b4aa1eeb"
    }
  },
  {
    "ts": null,
    "headline": "Multiple Myeloma Global and Regional Market Analysis and Forecast Report 2025-2035 | Johnson & Johnson, Sanofi, AbbVie, Bristol-Myers Squibb, Takeda, Pfizer Drive Innovation and Growth",
    "summary": "Multiple Myeloma is a cancer affecting plasma cells in bone marrow, often leading to weakened bones, anemia, and kidney damage. The production of abnormal M-proteins is a disease hallmark, detectable in blood or urine. While incurable, treatment advancements like chemotherapy, immunotherapy, and CAR T-cell therapy enhance patient outcomes. Market growth is driven by innovative immunotherapies, yet challenges like high treatment costs, resistance, and late diagnosis persist. Key players such as J",
    "url": "https://finnhub.io/api/news?id=9b792f2d80db8c118ae6948862869b5f26d134d3d1926bdd311f297bfab8402d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754905080,
      "headline": "Multiple Myeloma Global and Regional Market Analysis and Forecast Report 2025-2035 | Johnson & Johnson, Sanofi, AbbVie, Bristol-Myers Squibb, Takeda, Pfizer Drive Innovation and Growth",
      "id": 136292450,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Multiple Myeloma is a cancer affecting plasma cells in bone marrow, often leading to weakened bones, anemia, and kidney damage. The production of abnormal M-proteins is a disease hallmark, detectable in blood or urine. While incurable, treatment advancements like chemotherapy, immunotherapy, and CAR T-cell therapy enhance patient outcomes. Market growth is driven by innovative immunotherapies, yet challenges like high treatment costs, resistance, and late diagnosis persist. Key players such as J",
      "url": "https://finnhub.io/api/news?id=9b792f2d80db8c118ae6948862869b5f26d134d3d1926bdd311f297bfab8402d"
    }
  },
  {
    "ts": null,
    "headline": "FDA gives Arvinas and Pfizer’s vepdegestrant NDA for breast cancer",
    "summary": "Vepdegestrant is an investigational, oral bioavailable PROteolysis TArgeting Chimera (PROTAC) medication.",
    "url": "https://finnhub.io/api/news?id=cfcbe961aab7a34b58162c11b9729aac28e51a919803dc23fd1bd6bd3492c527",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754904467,
      "headline": "FDA gives Arvinas and Pfizer’s vepdegestrant NDA for breast cancer",
      "id": 136294378,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Vepdegestrant is an investigational, oral bioavailable PROteolysis TArgeting Chimera (PROTAC) medication.",
      "url": "https://finnhub.io/api/news?id=cfcbe961aab7a34b58162c11b9729aac28e51a919803dc23fd1bd6bd3492c527"
    }
  },
  {
    "ts": null,
    "headline": "Non-metastatic Prostate Cancer Market Analysis and Forecast, 2023-2035 | J&J, Astellas, Bristol-Myers Squibb, Pfizer, Merck, Bayer, Sanofi, Clovis, AstraZeneca, AbbVie, and Boehringer Lead Innovations",
    "summary": "The Non-metastatic Prostate Cancer market is witnessing substantial growth driven by increasing demand for targeted therapies and innovative treatment options. Non-metastatic prostate cancer, confined to the prostate gland, benefits from early detection methods like PSA testing and multiparametric MRI, facilitating timely intervention. Key players like Johnson & Johnson, Astellas Pharma, and Pfizer are pioneering advancements with androgen receptor inhibitors and precision medicine. Despite sign",
    "url": "https://finnhub.io/api/news?id=7ed66726fb860b103f275cf311c614095bcaca667705b72b586e98df5fdd96f9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754903580,
      "headline": "Non-metastatic Prostate Cancer Market Analysis and Forecast, 2023-2035 | J&J, Astellas, Bristol-Myers Squibb, Pfizer, Merck, Bayer, Sanofi, Clovis, AstraZeneca, AbbVie, and Boehringer Lead Innovations",
      "id": 136292298,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The Non-metastatic Prostate Cancer market is witnessing substantial growth driven by increasing demand for targeted therapies and innovative treatment options. Non-metastatic prostate cancer, confined to the prostate gland, benefits from early detection methods like PSA testing and multiparametric MRI, facilitating timely intervention. Key players like Johnson & Johnson, Astellas Pharma, and Pfizer are pioneering advancements with androgen receptor inhibitors and precision medicine. Despite sign",
      "url": "https://finnhub.io/api/news?id=7ed66726fb860b103f275cf311c614095bcaca667705b72b586e98df5fdd96f9"
    }
  },
  {
    "ts": null,
    "headline": "GSK climbs after winning FDA priority review for oral gonorrhoea antibiotic",
    "summary": "Investing.com -- GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review application for gepotidacin, an oral antibiotic aimed at treating sexually transmitted uncomplicated gonorrhoea.",
    "url": "https://finnhub.io/api/news?id=9c1ab6fb3a17c7cb54c0ffffcdb29f9fcbfc4ec2c605f7657ce41748e757ab9e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754900399,
      "headline": "GSK climbs after winning FDA priority review for oral gonorrhoea antibiotic",
      "id": 136292452,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Investing.com -- GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review application for gepotidacin, an oral antibiotic aimed at treating sexually transmitted uncomplicated gonorrhoea.",
      "url": "https://finnhub.io/api/news?id=9c1ab6fb3a17c7cb54c0ffffcdb29f9fcbfc4ec2c605f7657ce41748e757ab9e"
    }
  }
]